Logo image of MTNB

MATINAS BIOPHARMA HOLDINGS I (MTNB) Stock Fundamental Analysis

USA - NYSEARCA:MTNB - US5768103039 - Common Stock

1.29 USD
-0.05 (-3.73%)
Last: 11/4/2025, 3:12:56 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to MTNB. MTNB was compared to 534 industry peers in the Biotechnology industry. MTNB has a bad profitability rating. Also its financial health evaluation is rather negative. MTNB has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

MTNB had negative earnings in the past year.
MTNB had a negative operating cash flow in the past year.
MTNB had negative earnings in each of the past 5 years.
In the past 5 years MTNB always reported negative operating cash flow.
MTNB Yearly Net Income VS EBIT VS OCF VS FCFMTNB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

MTNB's Return On Assets of -212.28% is on the low side compared to the rest of the industry. MTNB is outperformed by 90.64% of its industry peers.
MTNB has a worse Return On Equity (-315.97%) than 71.72% of its industry peers.
Industry RankSector Rank
ROA -212.28%
ROE -315.97%
ROIC N/A
ROA(3y)-110.03%
ROA(5y)-80.29%
ROE(3y)-165.34%
ROE(5y)-115.52%
ROIC(3y)N/A
ROIC(5y)N/A
MTNB Yearly ROA, ROE, ROICMTNB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

MTNB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MTNB Yearly Profit, Operating, Gross MarginsMTNB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20K -40K -60K

More info and screens

3

2. Health

2.1 Basic Checks

MTNB does not have a ROIC to compare to the WACC, probably because it is not profitable.
MTNB has more shares outstanding than it did 1 year ago.
The number of shares outstanding for MTNB has been reduced compared to 5 years ago.
MTNB has a worse debt/assets ratio than last year.
MTNB Yearly Shares OutstandingMTNB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
MTNB Yearly Total Debt VS Total AssetsMTNB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

MTNB has an Altman-Z score of -29.39. This is a bad value and indicates that MTNB is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of MTNB (-29.39) is worse than 89.14% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that MTNB is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.00, MTNB perfoms like the industry average, outperforming 48.50% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -29.39
ROIC/WACCN/A
WACC8.73%
MTNB Yearly LT Debt VS Equity VS FCFMTNB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 4.07 indicates that MTNB has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 4.07, MTNB is in line with its industry, outperforming 46.63% of the companies in the same industry.
A Quick Ratio of 4.07 indicates that MTNB has no problem at all paying its short term obligations.
MTNB has a Quick ratio of 4.07. This is comparable to the rest of the industry: MTNB outperforms 48.31% of its industry peers.
Industry RankSector Rank
Current Ratio 4.07
Quick Ratio 4.07
MTNB Yearly Current Assets VS Current LiabilitesMTNB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

1

3. Growth

3.1 Past

MTNB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 24.18%, which is quite impressive.
MTNB shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)24.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.09%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, MTNB will show a very strong growth in Earnings Per Share. The EPS will grow by 57.54% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y63.31%
EPS Next 2Y-10.59%
EPS Next 3Y30.93%
EPS Next 5Y57.54%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MTNB Yearly Revenue VS EstimatesMTNB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2018 2019 2020 2021 2022 2023 2027 2028 2029 2030 2031 2032 200M 400M 600M
MTNB Yearly EPS VS EstimatesMTNB Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 50 -50 -100

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MTNB. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MTNB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MTNB Price Earnings VS Forward Price EarningsMTNB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MTNB Per share dataMTNB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4

4.3 Compensation for Growth

MTNB's earnings are expected to grow with 30.93% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.59%
EPS Next 3Y30.93%

More info and screens

0

5. Dividend

5.1 Amount

MTNB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MATINAS BIOPHARMA HOLDINGS I

NYSEARCA:MTNB (11/4/2025, 3:12:56 PM)

1.29

-0.05 (-3.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2025-08-12
Earnings (Next)11-11 2025-11-11
Inst Owners5.2%
Inst Owner Change0.15%
Ins Owners10.04%
Ins Owner Change0%
Market Cap7.16M
Revenue(TTM)N/A
Net Income(TTM)-24251000
Analysts45.71
Price TargetN/A
Short Float %1.8%
Short Ratio0.13
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.93
P/tB 1.32
EV/EBITDA N/A
EPS(TTM)-4.17
EYN/A
EPS(NY)-5.1
Fwd EYN/A
FCF(TTM)-1.99
FCFYN/A
OCF(TTM)-1.99
OCFYN/A
SpS0
BVpS1.38
TBVpS0.98
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -212.28%
ROE -315.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-110.03%
ROA(5y)-80.29%
ROE(3y)-165.34%
ROE(5y)-115.52%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.07
Quick Ratio 4.07
Altman-Z -29.39
F-Score3
WACC8.73%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)24.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.09%
EPS Next Y63.31%
EPS Next 2Y-10.59%
EPS Next 3Y30.93%
EPS Next 5Y57.54%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y15.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year8.5%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y31.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y29.01%
OCF growth 3YN/A
OCF growth 5YN/A

MATINAS BIOPHARMA HOLDINGS I / MTNB FAQ

Can you provide the ChartMill fundamental rating for MATINAS BIOPHARMA HOLDINGS I?

ChartMill assigns a fundamental rating of 1 / 10 to MTNB.


What is the valuation status for MTNB stock?

ChartMill assigns a valuation rating of 1 / 10 to MATINAS BIOPHARMA HOLDINGS I (MTNB). This can be considered as Overvalued.


Can you provide the profitability details for MATINAS BIOPHARMA HOLDINGS I?

MATINAS BIOPHARMA HOLDINGS I (MTNB) has a profitability rating of 0 / 10.